13 November 2023
AASLD, The Liver Meeting 2023, Boston, USA
The Scientific Program Committee of the American Association for the Study of Liver Diseases (AASLD)…
Read More
You have a question ?
19 April 2023
Genoscience Pharma has announced a new agreement for research at the Hebrew University of Jerusalem on targeted degradation technology
MARSEILLE-JERUSALEM, April 19, 2023 – Genoscience Pharma a clinical-stage biopharmaceutical company that develops disruptive therapeutics…
Read More
12 January 2023
J.P. Morgan Week – SAN FRANCISCO- 9 to 11 January 2023
J.P. Morgan Healthcare Week 2023 We participated both to the French Healthcare Corner organized by…
Read More
1 February 2023
ODD obtained by Genoscience Pharma from FDA to treat HCC
Genoscience Pharma receives FDA Orphan Drug Designation for ezurpimtrostat to treat HepatoCellular Carcinoma (HCC) Ezurpimtrostat…
Read More
6 January 2023
Genoscience Pharma announces the start of GNS561’s Phase 2b Clinical Trial
Genoscience Pharma announces launch of phase 2b clinical trial of ezurpimtrostat (GNS561) to treat hepatocarcinoma…
Read More
27 October 2022
Prix Galien USA 2022: Genoscience Pharma is nominated in the category “Start-up/Biotech”
Genoscience Pharma has been nominated to the Prix Galien USA 2022 A so excited event…
Read More
13 September 2022
Orphan Drug Designation to GNS561 for the treatment of Cholangiocarcinoma to GENFIT
Genoscience Pharma is proud that FDA granted an Orphan Drug Designation to GNS561 (a Genoscience's…
Read More
22 April 2022
BIOTRINITY – LONDON – 26-27th April 2022
Genoscience Pharma is enthusiastic, after having selected , about presenting the company during the Company…
Read More
3 March 2022
Liver Cancer, Phase 1b Clinical results publication
Major First in Class Clinical data! Genoscience is proud to announce a new cornerstone of…
Read More
17 January 2022
GNS561 Exhibits Potent Antiviral Activity against SARS-CoV-2 through Autophagy Inhibition
Since December 2019, SARS-CoV-2 has spread quickly worldwide, leading to more than 280 million confirmed…
Read More
